Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03929783 · ClinicalTrials.gov registry record · NA

Contrast Enhanced Mammography in Diagnosing Patients With Suspicious Breast Findings

A NA study of Breast Neoplasms, sponsored by Thomas Jefferson University.

Completed
Registry status
NA
Development phase
107
Enrollment target
1
Study location

NCT03929783 is a NA study of Breast Neoplasms that has completed, run by Thomas Jefferson University. The registered enrollment target is 107 participants, below the 568-participant average among 97 other Breast Neoplasms trials with a reported enrollment target (81% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03929783, a NA study of Breast Neoplasms, has completed, sponsored by Thomas Jefferson University.

COMPLETED
Registry status
NA
Development phase
107 participants
Enrollment target
1
Study location

Study Summary

This pilot trial studies how well contrast enhanced mammography works in diagnosing patients with suspicious breast findings. Diagnostic procedures, such as contrast enhanced mammography, may help to reclassify findings seen on diagnostic mammography and ultrasound as benign or likely benign with what would otherwise require biopsy for confirmation.

Conditions Studied

Interventions

  • PROCEDURE Contrast Enhanced Digital Mammography

Study Locations (1)

Pennsylvania

  • Sidney Kimmel Cancer Center at Thomas Jefferson University - Philadelphia

Trial Details

FieldValue
Enrollment Target 107 participants
Start Date 2020-06-23
Est. Completion 2023-01-27
Phase NA

Sponsor

Thomas Jefferson University

292 total trials

What the Registry Record Tells You About NCT03929783

The ClinicalTrials.gov registry entry for NCT03929783 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 107 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 568-participant average among 97 other Breast Neoplasms trials with a reported enrollment target (81% lower). The listed sponsor is Thomas Jefferson University, which has 292 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Breast Neoplasms appearing as the primary indexed condition, and to 1 intervention - of which Contrast Enhanced Digital Mammography is the first listed.

NCT03929783 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.

Frequently Asked Questions

What is clinical trial NCT03929783 about?

NCT03929783 is a clinical study titled "Contrast Enhanced Mammography in Diagnosing Patients With Suspicious Breast Findings". This pilot trial studies how well contrast enhanced mammography works in diagnosing patients with suspicious breast findings. Diagnostic procedures, such as contrast enhanced mammography, may help to reclassify findings seen on diagnostic mammography and ultrasound as benign or likely benign with wh...

What is the current status of trial NCT03929783?

This trial is currently completed. It is a NA study. The enrollment target is 107 participants. The study started on 2020-06-23. Estimated completion is 2023-01-27.

What conditions does trial NCT03929783 study?

This clinical trial studies the following conditions: Breast Neoplasms.

What interventions are being tested in trial NCT03929783?

The interventions under investigation include: Contrast Enhanced Digital Mammography (PROCEDURE).

Who is sponsoring clinical trial NCT03929783?

This trial is sponsored by Thomas Jefferson University, which has 292 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03929783 being conducted?

This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Breast Neoplasms

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.